RxDoctor Payments Data

Khadija Mamsa, MD

Internal Medicine · Carlsbad, NMNPI 1669744868

Payments from drug & device makers

$290in general payments, 2019–2025

Across 16 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$152
  • AstraZeneca$35
  • Novo Nordisk$34
  • Inspire Medical Systems, Inc.$30
  • Novartis$24
  • Amgen$16

What the payments were for

  • Food & beverage$25688%
  • Education$3512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$290 in reported general payments places this provider in the 70th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$202,118
Medicare patients
620
Services billed
2,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide147$248,547
TrulicityDulaglutide80$115,275
EliquisApixaban93$112,843
JardianceEmpagliflozin64$90,157
JanuviaSitagliptin Phosphate58$80,302
MounjaroTirzepatide46$65,046
FarxigaDapagliflozin Propanediol54$64,750
XareltoRivaroxaban21$27,795
Lantus SolostarInsulin Glargine,hum.Rec.Anlog98$12,636
Levothyroxine Sodium886$11,382
Atorvastatin Calcium758$9,227
Arnuity ElliptaFluticasone Furoate30$7,849
Breo ElliptaFluticasone/Vilanterol17$6,871
Losartan Potassium532$6,411
SymbicortBudesonide/Formoterol Fumarate24$6,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$248,547147 claims
AstraZenecaFarxiga, Symbicort$35$70,95378 claims
GSKArnuity Ellipta, Breo Ellipta$152$14,72047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Carlsbad

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →